Melanotan II is a synthetic tanning peptide that draws attention for the visible "before and after" skin-darkening it can produce. It also carries real safety concerns and is not an approved product anywhere. Here is an educational overview, reviewed and corrected on September 5, 2026, with the dated regulator actions and published case reports that earlier versions of this page left out.
Quick answer
Melanotan II is a lab-made peptide similar to a hormone (alpha-MSH) that stimulates the skin to produce more melanin, which darkens the skin and is the basis of the "before and after" tanning results people describe. It is not FDA-approved, and regulators have warned against unlicensed versions sold online. Reported effects include nausea, facial flushing and darkening or changes in moles and freckles, and published case reports describe melanoma, priapism, rhabdomyolysis, renal infarction and posterior reversible encephalopathy syndrome in users. It is not approved anywhere: FDA warned a U.S. seller in 2007 that it is an unapproved new drug, and Australia's TGA issued a safety alert on August 18, 2026 advising people to stop using it.
What is Melanotan II?
Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone that signals the skin's pigment cells (melanocytes) to produce melanin. By mimicking that signal, Melanotan II increases melanin production, which darkens the skin and is why it is marketed as a "tanning peptide."
It is sometimes called MT-2 or MT-II. It is not an approved drug, and the products sold online are unlicensed. In Australia it is a prescription-only substance with no products on the Australian Register of Therapeutic Goods, and in the United Kingdom its sale is illegal (International Journal of Oral and Maxillofacial Surgery, 2025). When Australia's TGA tested five seized nasal-spray bottles labelled 30 mg, they contained between 22 and 54 mg of melanotan II per 20 mL (TGA alert, August 18, 2026), so purity, dose and safety are not just unregulated but unknown.
Melanotan II before and after: what changes?
The most visible change people report is skin darkening, the basis of before-and-after comparisons. There is no approved product and no controlled human efficacy data, so every 'result' is anecdotal, and because tested products contained anywhere from 22 to 54 mg per bottle against a 30 mg label (TGA, August 2026), two users of the same brand may not even be taking the same dose. The degree and evenness of the result vary widely from person to person.
From the FormBlends catalog
Melanotan II
Melanocortin peptide for UV-free skin pigmentation · From $29/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
Learn about Melanotan II →Other commonly reported changes include darkening of existing moles, freckles, and other pigmented spots, and the appearance of new dark spots. This is one of the reasons regulators and dermatologists raise concern, since changes in moles can complicate skin-cancer monitoring.
What is the timeline?
Results are gradual rather than instant. Anecdotal reports describe pigmentation building over days to weeks with continued use; no study has validated a timeline. There is no fixed, validated timeline because the product is unregulated and individual responses differ. Importantly, the absence of large, controlled human studies means there is no reliable, standardized "before and after" schedule, only anecdotal reports.
Reported side effects and safety concerns
Melanotan II is associated with a range of side effects, and the safety concerns are significant enough that multiple regulators have issued warnings.
- Nausea, especially early in use.
- Facial flushing and skin reactions.
- Darkening or changes in moles and freckles, plus new pigmented spots.
- Priapism, a prolonged erection that is a medical emergency, reported in published cases (BMJ Case Reports, 2019; Sexual Medicine, 2021), plus appetite suppression, since melanocortin pathways touch multiple systems.
Because online products are unlicensed, there is added risk from unknown purity and dose. Published case reports also describe cutaneous melanoma in users (British Journal of Dermatology, 2011; Dermatology, 2014), oral mucosal melanoma after nasal-spray use (International Journal of Oral and Maxillofacial Surgery, 2025), rhabdomyolysis with sympathomimetic toxicity after a 6 mg injection (Clinical Toxicology, 2012), renal infarction (CEN Case Reports, 2020), posterior reversible encephalopathy syndrome (Annals of Internal Medicine, 2013) and persistent gum pigmentation (Life, 2026). Case reports cannot prove cause, but they are the human safety evidence that exists. Anyone noticing changes in a mole should see a dermatologist.
Comparison: Melanotan II vs conventional tanning
| Method | How it works | Key concerns |
|---|---|---|
| Melanotan II | Stimulates melanin via alpha-MSH analog | Not FDA-approved, unregulated, mole changes, nausea |
| UV tanning (sun/beds) | UV exposure triggers melanin | Skin damage, skin-cancer risk |
| Sunless tanner (DHA) | Surface dye reaction, no melanin change | Cosmetic only, no melanin involvement |
Why regulators have warned about it
The FDA has never approved Melanotan II. On or about August 30, 2007 FDA sent a warning letter to Melanocorp stating that the product was a new drug that could not be introduced without an approved application, a history FDA set out in a 2016 Notice of Opportunity for Hearing. Australia's TGA has said since at least January 2023 that it has not approved MT-II and that development was halted for safety reasons, and on August 18, 2026 it issued a safety alert after laboratory testing of seized nasal sprays, advising users to stop and dispose of the products. The concerns center on unknown safety, unregulated manufacturing, and the potential for serious effects, including the complication of monitoring skin for cancer when moles darken or change. For these reasons, it is widely advised to avoid unlicensed products and to consult a medical professional before considering anything in this category.
Where FormBlends fits
FormBlends focuses on evidence-based health and metabolic information. While Melanotan II falls outside that scope, if your interest is in medically supervised wellness and weight management, FormBlends keeps plain-language guides on compounded semaglutide and a provider comparison tool.
Regulator actions, with dates
| Date | Regulator | Action |
|---|---|---|
| On or about August 30, 2007 | U.S. FDA | Warning letter to Melanocorp: melanotan II is a new drug that cannot be introduced without an approved application; the company acknowledged the letter on December 14, 2007 (recorded in FDA's 2016 Notice of Opportunity for Hearing) |
| August 5, 2016 | U.S. FDA | Notice of Opportunity for Hearing setting out the 2007 history and noting some melanotan II was imported from China |
| January 2023 | Australia's TGA | Public statements that MT-II is not approved, that development was halted for safety reasons, and that it is illegal to advertise or supply in Australia (as reported by UNSW, January 30, 2023) |
| August 18, 2026 | Australia's TGA | Safety alert after testing five seized nasal-spray bottles: 22 to 54 mg of melanotan II per 20 mL against a 30 mg label; no products on the ARTG; advice to stop use and dispose (as reported by RACGP newsGP) |
| 2025 | United Kingdom | Sale described as illegal in a published case report (International Journal of Oral and Maxillofacial Surgery, 2025) |
Documented serious harms in published case reports
There are no controlled human trials of melanotan II, so the safety record is case reports. They cannot prove that the product caused the event, but they are what exists as of September 5, 2026.
| Event | Report |
|---|---|
| Cutaneous melanoma | Paurobally et al., British Journal of Dermatology 2011;164(6):1403-1405 (PMID 21564053); Hjuler and Lorentzen, Dermatology 2014;228(1):34-36 (PMID 24355990), a 20-year-old woman after a 3 to 4 week course plus sunbeds |
| Oral mucosal malignant melanoma after nasal spray | International Journal of Oral and Maxillofacial Surgery 2025;54(9):806-808 (PMID 40210573), a 22-year-old woman |
| Priapism | Dreyer et al., BMJ Case Reports 2019;12(2):e227644 (PMID 30796078); Mallory et al., Sexual Medicine 2021;9(1):100298 (PMID 33460908) |
| Rhabdomyolysis with sympathomimetic toxicity | Nelson et al., Clinical Toxicology 2012;50(10):1169-1173 (PMID 23121206), a 39-year-old man after a 6 mg injection, heart rate 146 |
| Renal infarction | Peters et al., CEN Case Reports 2020;9(2):159-161 (PMID 31953620) |
| Posterior reversible encephalopathy syndrome | Kaski et al., Annals of Internal Medicine 2013;158(9):707-708 (PMID 23648958) |
| Persistent oral and gingival pigmentation | Bonchev, Life 2026;16(2):265, pigment persisting three months after stopping |
Why 'before and after' cannot be standardized
Three things stand between any melanotan II photo and a reliable expectation. First, there is no approved product, so there is no labelled dose or release specification. Second, the products people actually buy vary: the TGA's August 2026 testing found 22 to 54 mg per bottle where the label said 30 mg. Third, there are no controlled human efficacy studies, only anecdotes and secondary summaries such as DermNet NZ's note that darkening is reported within roughly the first five doses. A 'timeline' built on those inputs describes someone else's unknown dose of an unverified product.
Frequently asked questions
What does Melanotan II do?
It stimulates the skin to produce more melanin by mimicking alpha-MSH, which darkens the skin (the tanning effect).
Is Melanotan II FDA-approved?
No. FDA told a U.S. seller in a warning letter dated on or about August 30, 2007 that melanotan II is an unapproved new drug, and regulators in Australia and the UK treat its sale as illegal.
What are the before-and-after results?
The main visible change is skin darkening over days to weeks. Results vary, and there is no validated standardized timeline.
Does Melanotan II affect moles?
Yes, it can darken existing moles and freckles and cause new dark spots. Any mole changes should be checked by a dermatologist.
What are the side effects of Melanotan II?
Commonly reported: nausea, facial flushing and pigment changes. Published case reports: melanoma, oral mucosal melanoma, priapism, rhabdomyolysis, renal infarction and posterior reversible encephalopathy syndrome (see Sources).
Does Melanotan II affect hair?
It primarily affects skin pigment. Some users discuss other effects, but the well-documented action is on melanin production in the skin.
Is Melanotan II safe?
No regulator has approved it, and published case reports describe melanoma, priapism, rhabdomyolysis and other serious harms in users. Australia's TGA advised people to stop using melanotan II products on August 18, 2026. FormBlends does not recommend it.
How is it different from sunless tanner?
Sunless tanners are surface dyes that do not change melanin. Melanotan II actually stimulates melanin production in the skin.
What did the TGA find when it tested melanotan II products in 2026?
Australia's Therapeutic Goods Administration analysed five seized nasal-spray bottles and found 22 to 54 mg of melanotan II per 20 mL bottle against a labelled 30 mg, according to its August 18, 2026 safety alert as reported by RACGP newsGP. The TGA noted there are no melanotan II products on the Australian Register of Therapeutic Goods, said the products may pose serious health risks, and advised users to stop and dispose of them.
Has melanotan II been linked to skin cancer?
Published case reports describe cutaneous melanoma in melanotan users (British Journal of Dermatology, 2011; Dermatology, 2014, a 20-year-old woman after a 3 to 4 week course plus sunbeds) and oral mucosal melanoma in a 22-year-old woman using a nasal spray (International Journal of Oral and Maxillofacial Surgery, 2025). Case reports cannot prove cause, but darkening and changing moles also make skin-cancer monitoring harder, which is why dermatologists and regulators warn against it.
Related guides
- BPC-157 Before and After: Real Results and Timeline
- Peptides for Muscle Growth Before and After: Real Results Explained | FormBlends
- AOD 9604 Peptide Before and After: Real Results, Evidence Rated | FormBlends
- BPC-157 Peptide Before and After: Real Results, Evidence Grades | FormBlends
- MOTS-C Peptide Before and After: Real Results, Evidence & What to Expect | FormBlends
- Peptides for Weight Loss Before and After: Real Results Data | FormBlends
- Tool: weight-loss timeline tool
Sources
- U.S. Food and Drug Administration. Notice of Opportunity for Hearing (Manookian), August 5, 2016, recording the warning letter to Melanocorp dated on or about August 30, 2007 that melanotan II is an unapproved new drug. https://www.fda.gov/regulatory-information/electronic-reading-room/notice-opportunity-hearing-nooh-manookian-edward-8516
- DermNet NZ. Melanotan II (topic page). https://dermnetnz.org/topics/melanotan-ii
- RACGP newsGP. TGA issues urgent melanotan II tanning product warning, August 18, 2026 (five seized nasal sprays contained 22 to 54 mg per 20 mL versus 30 mg labelled). https://www1.racgp.org.au/newsgp/clinical/tga-issues-urgent-melanotan-ii-tanning-product-war
- UNSW Newsroom. What is melanotan II, the drug that the TGA urges consumers to avoid, January 30, 2023. https://www.unsw.edu.au/newsroom/news/2023/01/what-is-melanotan-ii---the-drug-that-the-tga-urges-consumers-to-
- Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014;228(1):34-36. PubMed PMID 24355990.
- Paurobally D et al. Melanotan-associated melanoma. British Journal of Dermatology. 2011;164(6):1403-1405. PubMed PMID 21564053.
- Oral mucosal malignant melanoma after melanotan II nasal spray in a 22-year-old woman. International Journal of Oral and Maxillofacial Surgery. 2025;54(9):806-808. PubMed PMID 40210573.
- Nelson ME et al. Melanotan II injection with sympathomimetic toxicity and rhabdomyolysis. Clinical Toxicology. 2012;50(10):1169-1173. PubMed PMID 23121206.
- Dreyer BA et al. Melanotan-induced priapism. BMJ Case Reports. 2019;12(2):e227644. PubMed PMID 30796078.
- Mallory C et al. Priapism after melanotan tanning injection. Sexual Medicine. 2021;9(1):100298. PubMed PMID 33460908.
- Peters B et al. Melanotan II as a possible cause of renal infarction. CEN Case Reports. 2020;9(2):159-161. PubMed PMID 31953620.
- Kaski JP et al. Melanotan and posterior reversible encephalopathy syndrome. Annals of Internal Medicine. 2013;158(9):707-708. PubMed PMID 23648958.
- Bonchev G. Oral mucosal pigmentation after melanotan II use. Life. 2026;16(2):265. https://pmc.ncbi.nlm.nih.gov/articles/PMC12942211/
Ready when you are
Melanotan II
Melanocortin peptide for UV-free skin pigmentation · From $29/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
Learn about Melanotan II →